netFormulary NHS
North East and North Cumbria
ICS Formulary
 Search
 Results

Looking for Rivaroxaban found 21 matches

Formulary items 6 matches
   
Open monograph to display formulary status BNF Category
  Rivaroxaban Cardiovascular system - Oral anticoagulants - 02.08.02
  Rivaroxaban
(For CAD/PAD) 		Cardiovascular system - Oral anticoagulants - 02.08.02
  Andexanet alfa  (Ondexxya®) Cardiovascular system - Oral anticoagulants - 02.08.02
  Apixaban Cardiovascular system - Oral anticoagulants - 02.08.02
  Dabigatran Cardiovascular system - Oral anticoagulants - 02.08.02
  Edoxaban Cardiovascular system - Oral anticoagulants - 02.08.02
 


Linkslink in drug section Link to Drug Section link in subsection Link to document
link in drug section MHRA Drug Safety Update Dec 2014: New oral anticoagulants apixaban (Eliquis▼), dabigatran (Pradaxa) and rivaroxaban (Xarelto▼) (02.08.02)
link in drug section MHRA Drug Safety Update Dec 2014: New oral anticoagulants apixaban (Eliquis▼), dabigatran (Pradaxa) and rivaroxaban (Xarelto▼) (02.08.02)
link in drug section MHRA Drug Safety Update Dec 2014: New oral anticoagulants apixaban (Eliquis▼), dabigatran (Pradaxa) and rivaroxaban (Xarelto▼) (02.08.02)
link in drug section MHRA Drug Safety Update Dec 2014: New oral anticoagulants apixaban (Eliquis▼), dabigatran (Pradaxa) and rivaroxaban (Xarelto▼) (02.08.02)
link in drug section MHRA Drug Safety Update July 2019: Rivaroxaban (Xarelto▼): reminder that 15 mg and 20 mg tablets should be taken with food (02.08.02)
link in drug section MHRA Drug Safety Update July 2019: Rivaroxaban (Xarelto▼): reminder that 15 mg and 20 mg tablets should be taken with food (02.08.02)
link in drug section MHRA Drug Safety Update Oct 2018: Rivaroxaban (Xarelto▼) after transcatheter aortic valve replacement: increase in all-cause mortality, thromboembolic and bleeding events in a clinical trial (02.08.02)
link in drug section MHRA Drug Safety Update Oct 2018: Rivaroxaban (Xarelto▼) after transcatheter aortic valve replacement: increase in all-cause mortality, thromboembolic and bleeding events in a clinical trial (02.08.02)
link in drug section NICE TA170: Rivaroxaban for the prevention of venous thromboembolism after total hip or total knee replacement in adults (02.08.02)
link in drug section NICE TA256: Rivaroxaban for the prevention of stroke and systemic embolism in people with atrial fibrillation (02.08.02)
link in drug section NICE TA261: Rivaroxaban for the treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism (02.08.02)
link in drug section NICE TA287: Rivaroxaban for treating pulmonary embolism and preventing recurrent venous thromboembolism (02.08.02)
link in drug section NICE TA335: Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome (02.08.02)
link in drug section NICE TA607: Rivaroxaban for preventing atherothrombotic events in people with coronary or peripheral artery disease (02.08.02)
link in drug section NICE TA697: Andexanet alfa for reversing anticoagulation from apixaban or rivaroxaban (02.08.02)


 
netFormulary